# OnCo record paper-stampede-lancet-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-stampede-lancet-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-stampede-lancet-2016" ;
  schema:name "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial"@en ;
  schema:description "Published report from the STAMPEDE trial registered as NCT00268476, in The Lancet (2016), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-stampede-lancet-2016/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(15)01037-5>, <https://pubmed.ncbi.nlm.nih.gov/26719232/>, <https://europepmc.org/article/MED/26719232>, <https://clinicaltrials.gov/study/NCT00268476> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(15)01037-5> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "James ND, Sydes MR, Clarke NW, et al." ;
  onco:trials <https://onco.cc/trials/stampede/> ;
  onco:journals <https://onco.cc/journals/lancet/> .